Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704705 | 0.92 | MCHR1 (0.57) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6223309 | 0.86 | MCHR1 (0.47) | MCHR1NPC1RAB9ACYP2D6KDM4E | |
| SCHEMBL6706824 | 0.86 | MCHR1 (0.56) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6705801 | 0.86 | MCHR1 (0.60) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6706763 | 0.85 | MCHR1 (0.72) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6705951 | 0.84 | MCHR1 (0.66) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6708072 | 0.84 | MCHR1 (0.60) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6706726 | 0.84 | MCHR1 (0.71) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6704702 | 0.81 | MCHR1 (0.57) | MCHR1NPC1RAB9ACYP2D6CHRM1 | |
| SCHEMBL6706057 | 0.81 | MCHR1 (0.59) | MCHR1NPC1RAB9ACYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | MCHR1 2/4885NPC1 2495/4885RAB9A 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.